Clinical Updates in Systemic Lupus Erythematosus
Improved Diagnostic and Management Strategies
Meeting Slides
Guidelines
The 1982 revised criteria for the classification of systemic lupus erythematosus
These guideline statements revise the original criteria from 1971 on the classification of systemic lupus erythematosus.
Tan EM, et al. Arthritis Rheum. 1982;25:1271-1277.
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.
ACR-recommended management strategies for lupus nephritis in adults, based on interventions that were available in the United States as of April 2011.
Hahn BH, et al. Arthritis Care Res (Hoboken). 2012;64:797-808.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
The SLICC updated and validated the 1997 revision of the ACR criteria. The classification criteria were expanded to 17, including clinical and immunologic subsets. A positive classification of SLE requires the appearance of 4 of the criteria with at least 1 clinical and 1 immunologic item.
Petri M, et al. Arthritis Rheum. 2012;64:2677-2686.
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
12 key recommendations from a EULAR task force on the diagnosis, management, and monitoring of SLE.
Bertsias G, et al. Ann Rheum Dis. 2008;67:195-205.
Tools
Systemic Lupus Erythematosus Responder Index
The evidence-based SLE Responder Index measures improvement in specific organs and overall disease activity. It is a composite of the Systemic Lupus Erythematosis Disease Activity Index, Physician’s Global Assessment, and the British Isles Lupus Assessment Group.
Furie RA, et al. Arthritis Rheum. 2009;61:1143-1151.
Patient Materials
The Lupus Companion
A free app to help people with lupus keep track of their medications, appointments, and symptoms. The Lupus Companion was developed as part of the Lupus Initiative, a program to educate healthcare professionals about diagnosing and treating lupus.
What You Should Know About Lupus
An educational brochure for patients with SLE from the S.L.E. Lupus Foundation. The pamphlet contains useful facts on disease, treatment, diagnosis, and outcomes.
Suggested Readings
Developments in the clinical understanding of lupus
Crow MK. Arthritis Res Ther. 2009;11:245.
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
Hochberg MC. Arthritis Rheum. 1997;40:1725.
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future
Jacob N, Stohl W. Autoimmunity. 2010;43:84-97.
Cytokine disturbances in systemic lupus erythematosus
Jacob N, Stohl W. Arthritis Res Ther. 2011;13:228.
Novel therapeutic agents in clinical development for systemic lupus erythematosus
Jordan N, et al. BMC Med. 2013;11:120.
Unmet medical needs in systemic lupus erythematosus
Lateef A, Petri M. Arthritis Res Ther. 2012;14:S4.
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Mosca M, et al. Ann Rheum Dis. 2010;69:1269-1274.
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Parker B, et al. Ann Rheum Dis. 2013;72:1308-1314.
Monitoring systemic lupus erythematosus in standard clinical care
Petri M. Best Pract Res Clin Rheumatol. 2007;21:687-697.
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between Belimumab and other inhibitors in development?
Stohl W. Curr Rheumatol Rep. 2012;14:303-309.
Systemic lupus erythematosus
Tsokos GJ. N Engl J Med. 2011;365:2110-2121.
Interactive PresentationScientific and Clinical Insights Into the Pathophysiology of Systemic Lupus Erythematosus
William Stohl, MD, PhD
Improved Diagnostic and Management Strategies
Relevant Resources
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
